Abudayyeh OO, Gootenberg JS, Essletzbichler P, et al. RNA targeting with CRISPR-Cas13. Nature. 2017;550(7675):280-284. doi:10.1038/nature24049.
Komor AC, Badran AH, Liu DR. Editing the Genome Without Double-Stranded DNA Breaks. ACS Chem Biol. 2018;13(2):383-388. doi:10.1021/acschembio.7b00710.
Nishimasu H, Yamano T, Gao L, Zhang F, Ishitani R, Nureki O. Structural Basis for the Altered PAM Recognition by Engineered CRISPR-Cpf1. Mol Cell. 2017;67(1):139-147.e2. doi:10.1016/j.molcel.2017.04.019.
Yamano T, Zetsche B, Ishitani R, Zhang F, Nishimasu H, Nureki O. Structural Basis for the Canonical and Non-canonical PAM Recognition by CRISPR-Cpf1. Mol Cell. 2017;67(4):633-645.e3. doi:10.1016/j.molcel.2017.06.035.
Myhrvold C, Freije CA, Gootenberg JS, et al. Field-deployable viral diagnostics using CRISPR-Cas13. Science. 2018;360(6387):444-448. doi:10.1126/science.aas8836.
Gootenberg JS, Abudayyeh OO, Kellner MJ, Joung J, Collins JJ, Zhang F. Multiplexed and portable nucleic acid detection platform with Cas13, Cas12a, and Csm6. Science. 2018;360(6387):439-444. doi:10.1126/science.aaq0179.
Gaudelli NM, Komor AC, Rees HA, et al. Programmable base editing of A•T to G•C in genomic DNA without DNA cleavage. Nature. 2017;551(7681):464-471. doi:10.1038/nature24644.
Pyzocha NK, Chen S. Diverse Class 2 CRISPR-Cas Effector Proteins for Genome Engineering Applications. ACS Chem Biol. 2018;13(2):347-356. doi:10.1021/acschembio.7b00800.
Gao X, Tao Y, Lamas V, et al. Treatment of autosomal dominant hearing loss by in vivo delivery of genome editing agents. Nature. 2018;553(7687):217-221. doi:10.1038/nature25164.
Weidmann AG, Choudhary A. Special Issue on the Chemical Biology of CRISPR. ACS Chem Biol. 2018;13(2):283-284. doi:10.1021/acschembio.8b00134.